ADMA Biologics, Inc.
NASDAQ:ADMABiotechnology
+$0.04 today
- Market cap
- $2.96B
- Beta
- 0.73
- P/E (TTM)
- 12.1
- EPS (TTM)
- $0.70
Volume 3.62M
Average 7.07M
Returns on capital
ADMA Biologics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
30.8%
avg -226.3%
ROIC
27.6%
avg -29.9%
ROA
23.5%
avg -30.6%
Analysis
ROE is currently the strongest return metric at 30.8% versus its period average of -226.3%. 3 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Adam S. Grossman | Co-Founder, President, Chief Executive Officer & Director | USD 2.14M | 49 | 585.95K | 0.25% |
Kaitlin Kestenberg | Chief Operating Officer & Senior Vice President of Compliance | USD 988.66K | 39 | — | — |
Jerrold Grossman | Co-Founder & Vice Chairman of the Board | USD 90K | 78 | — | — |
Terence Kohler | Chief Financial Officer & Treasurer | USD 46.97K | — | — | — |
Skyler Bloom | Senior Director of Business Development & Corporate Strategy | — | — | — | — |
Michael Goldstein | General Counsel | — | — | — | — |
John Hafl | Executive Director of Sales | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Nov 5, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
5
$468,294.00
Sells
9
$2.99M
Net Transaction Value
−$2.53M
Net selling
Most Active
Grossman Adam S
8 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Nov 5, 26Nov 5, 2026 | Grossman Adam S Direct | Sell | $1.3M$1,260,000.00 |
| Nov 5, 26Nov 5, 2026 | Grossman Adam S Direct | Sell | $504K$504,000.00 |
| May 27, 26May 27, 2026 | Grossman Jerrold B Direct | Buy | $50.6K$50,624.00 |
| May 12, 26May 12, 2026 | Grossman Jerrold B Direct | Buy | $100.1K$100,125.00 |
| May 11, 26May 11, 2026 | Grossman Jerrold B Direct | Buy | $100.1K$100,125.00 |
| Mar 16, 26Mar 16, 2026 | Grossman Adam S Direct | Sell | $227.4K$227,400.00 |
| Mar 16, 26Mar 16, 2026 | Grossman Adam S Direct | Sell | $91K$90,960.00 |
| Mar 9, 26Mar 9, 2026 | Kestenberg-Messina Kaitlin M. Direct | Sell | $157.8K$157,800.48 |
| Mar 6, 26Mar 6, 2026 | ELMS STEVE Indirect | Buy | $107.7K$107,730.00 |
| Mar 5, 26Mar 5, 2026 | ELMS STEVE Indirect | Buy | $109.7K$109,690.00 |
1–10 of 14
Summary
Insiders reported 5 buys worth $468,294.00 and 9 sells worth $2.99M over the last 12 months. That adds up to net selling of $2.53M. Grossman Adam S was the most active insider with 8 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | +22.1% (5yr)1 analysts |
| Revenue | N/A | N/A | +49.0% | +11.9% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | +22.1% (5yr)2 analysts |
| EBIT | N/A | N/A | N/A | +22.1% (5yr)2 analysts |
Analysis
Recent growth has been strongest in Revenue at +49.0% over three years. Forward estimates point to EBIT at +22.1% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Who does ADMA Biologics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about ADMA's management, answered from reported figures.
Who manages ADMA?
ADMA Biologics, Inc. (ADMA) lists 7 active executives. The top listed executive is Jerrold Grossman, Co-Founder & Vice Chairman of the Board.
Are ADMA insiders buying or selling?
Recent insider activity shows net selling of $3.66M.
Continue the stock analysis
Jump to another research area for this company.